Other therapy.

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Read More

2024-03-25T09:23:03-04:00November 1st, 2015|BluePrint, Evidence, Other|

Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients

PUBLICATION: Breast Care 2015;10:118-122 https://doi.org/10.1159/000376562. AUTHORS: Shimizu H., Horimoto Y., Read More

2024-03-25T09:25:03-04:00March 1st, 2015|Evidence, MammaPrint, Other, Racial Disparities|

Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective

PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Read More

2024-03-25T11:22:23-04:00September 12th, 2014|Evidence, Healthcare Economics, MammaPrint, Other|

Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retรจl Read More

2024-03-25T10:45:47-04:00June 18th, 2013|Adjuvant, Evidence, MammaPrint, MINDACT, Other|

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub Read More

2024-03-25T10:47:25-04:00June 1st, 2013|Evidence, Healthcare Economics, MammaPrint, Other|
Go to Top